These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 36897268)

  • 1. Editorial: Appraising liver fibrosis with eagle eyes.
    Wong GL
    J Gastroenterol Hepatol; 2023 Mar; 38(3):343. PubMed ID: 36897268
    [No Abstract]   [Full Text] [Related]  

  • 2. Appraising diagnostic performance of ELF test by pathological staging and digital quantification of liver fibrosis.
    Gunes Yegin E; Durusoy SS; Ture Ozdemir F; Kombak EF; Ataizi-Celikel C; Ozdogan OC
    Ann Hepatol; 2019; 18(6):833-840. PubMed ID: 31558418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: the impact of steatosis on liver stiffness quantification is minimal.
    Hassan A; Tapper EB
    Aliment Pharmacol Ther; 2018 May; 47(10):1416-1417. PubMed ID: 29676011
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: Hepatic immune response underlying liver cirrhosis and portal hypertension.
    Guo Y; Ma X; Nie Y; Kostallari E; Gao J
    Front Immunol; 2023; 14():1174562. PubMed ID: 36969230
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: optimising non-invasive screening for advanced liver fibrosis in NAFLD.
    Khan RS; Newsome PN
    Aliment Pharmacol Ther; 2017 Nov; 46(9):899-900. PubMed ID: 29023886
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial: in vino veritas-- transient elastography for staging liver fibrosis in alcoholic liver disease.
    Thiele M; Krag A
    Aliment Pharmacol Ther; 2016 May; 43(9):1014-5. PubMed ID: 27040164
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial: in vino veritas--transient elastography for staging liver fibrosis in alcoholic liver disease--authors' reply.
    Pavlov C; Casazza G; Nikolova D; Gluud C
    Aliment Pharmacol Ther; 2016 May; 43(9):1015-6. PubMed ID: 27040165
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease-not a simple choice?
    Neil Guha I; Patel K
    Aliment Pharmacol Ther; 2020 Jan; 51(1):179-180. PubMed ID: 31850556
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: stepwise risk stratification for both F3 and F4 fibrosis stage in NAFLD patients.
    Idriss R; Lai M
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1317-1318. PubMed ID: 30488626
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial: the impact of steatosis on liver stiffness quantification is minimal-Authors' reply.
    Karlas T; Petroff D; Wiegand J
    Aliment Pharmacol Ther; 2018 May; 47(10):1417-1418. PubMed ID: 29676009
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes.
    Fan W; Torok NJ
    Hepatol Commun; 2021 Apr; 5(4):553-555. PubMed ID: 33860113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial Fibrosis and Inflammation in Liver Cirrhosis: MRI Study of the Liver-Heart Axis.
    Isaak A; Praktiknjo M; Jansen C; Faron A; Sprinkart AM; Pieper CC; Chang J; Fimmers R; Meyer C; Dabir D; Thomas D; Trebicka J; Attenberger U; Kuetting D; Luetkens JA
    Radiology; 2020 Oct; 297(1):51-61. PubMed ID: 32808886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological evaluation of liver fibrosis and cirrhosis regression.
    Lo RC; Kim H
    Clin Mol Hepatol; 2017 Dec; 23(4):302-307. PubMed ID: 29281870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Present situation on non-invasive assessment of liver fibrosis/cirrhosis].
    Zhang QD; Lu LG
    Zhonghua Gan Zang Bing Za Zhi; 2018 May; 26(5):325-327. PubMed ID: 29996197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on cirrhosis of the liver. IV. The relations between the mortality from liver cirrhosis and the mortality from alcoholism, and between the mortality from liver cirrhosis and alcoholic consumption.
    NAKAMURA T; NAKAMURA S; KAWAMURA E; KANEKO T; SUGAWARA K; KATAKURA Y; ISONO T; SUZUKI I
    Tohoku J Exp Med; 1958 Apr; 67(4):365-71. PubMed ID: 13581054
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: Advances in Liver Inflammation and Fibrosis Due to Infectious Diseases.
    Oliveira SC; Delpino MV; Giambartolomei GH; Quarleri J; Splitter G
    Front Immunol; 2020; 11():1760. PubMed ID: 32849629
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial: can quantitative fibrosis assessment be used to enhance prediction of outcomes in patients with alcohol-related liver disease? Authors' reply.
    Israelsen M; Guerrero Misas M; Tsochatzis EA
    Aliment Pharmacol Ther; 2021 Jan; 53(1):185-186. PubMed ID: 33333595
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock?
    Stine JG; Rinella ME
    Am J Gastroenterol; 2017 May; 112(5):752-754. PubMed ID: 28469217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis?
    Horn P; Newsome PN
    Aliment Pharmacol Ther; 2020 May; 51(10):987-988. PubMed ID: 32338785
    [No Abstract]   [Full Text] [Related]  

  • 20. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C.
    Stauber RE; Lackner C
    World J Gastroenterol; 2007 Aug; 13(32):4287-94. PubMed ID: 17708599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.